Fetal Blood Sampling
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All fetal scalp lactate measurements should be interpreted taking into account: 
Indications
Suspected fetal compromise suggested by an abnormal CTG pattern 4, 14 .
Contraindications
 clear evidence on continuous EFM of serious, sustained fetal compromise  fetal bleeding disorders (e.g. suspected fetal thrombocytopaenia, haemophilia)
 face or brow presentation or uncertain presenting part  maternal infection (eg HIV, hepatitis virus, and herpes simplex virus and suspected intrauterine sepsis) NB: GBS+ve does not preclude FBS 4  suspected intrauterine sepsis  gestation less than 34 weeks' gestation 4  The effect of gestational age on the development of lactic acidosis due to hypoxia remains to be investigated. 
Management
 Ensure that the Lactate Pro TM machine is available, calibrated and functioning.
 The membranes must be ruptured and the cervix at least 3 cm dilated for the procedure to be attempted.
 Other technical considerations include the amount of effacement, station, application of the vertex to the cervix, volume of amniotic fluid and amount of baby hair  This procedure may be uncomfortable and intrusive for the woman. It is invasive to the fetus.
 Explain the procedure to the woman and obtain verbal consent.
 Assemble the equipment on the trolley  Place the woman in the left-lateral position or in lithotomy with a wedge under the right hip to reduce the risk of supine hypotension.
 Sampling is performed under direct vision via an amnioscope to avoid contamination with amniotic fluid.
 The incision site is carefully cleaned and a thin layer of petroleum jelly is applied.
 The baby's fontanelles should be avoided.
 Disposable blades, fixed in a plastic mount are used in a blade holder from which the blade does not protrude more than 2mm.
 A 2mm fetal scalp incision is made with steady pressure of the blade.
 The blood is collected in pre-heparinised glass capillary tubes.
 Pressure is applied to the incision site with a dry swab until the bleeding stops.
 Discard the blade in the sharps container.
 Document the procedure, the result and the subsequent plan of management.
 Postnatal examination of the baby should include examination of the sampling site.
Lactate Pro TM uses whole blood for analysis.
Lactate analysis of a blood sample collected in a glass capillary should be carried out within ten minutes of sampling because lactate increases linearly with time 8 .
Accuracy with the Lactate Pro TM has been tested on fetal blood and it has a between run co-efficient of variation (CV) of less than 4% 9 . A possible source of error in the analysis is contamination with amniotic fluid which contains high concentrations of lactate but the risk of amniotic fluid contamination is small due to the small blood sample volume needed.
The recommended intervention cut-off value of 4.8 mmol/L measured with the Lactate Pro TM is considerably higher than the cut-off value of 4.2 mmol/L recommended following an observational Australian study using the Accusport and highlights the importance of being familiar with the device in use in any unit 15 16 . 
Interpretation of values

Complications
Complications of FBS are very rare and include haemorrhage, infection and breakage of the blade
17
. The incision site should be observed carefully until all bleeding has ceased. If significant bleeding persists the baby should be delivered. A baby's blood volume ranges from 70-100mls/kg. Advise the neonatologist and consider an underlying haematological abnormality
18
. Postnatal examination of the baby should include examination of the sampling site.
Post Birth
Ensure that paired arterial and venous cord blood samples are collected following the birth of the baby and sent to the laboratory for blood gas analysis. These results need to be reviewed and added to the clinical notes.
Evaluation, monitoring and reporting of compliance to this guideline
Compliance to this guideline will be monitored by incidents reported through VHIMS.
References
Legislation/Regulations related to this guideline
Not applicable. 
Appendices
PGP Disclaimer Statement
The Royal Women's Hospital Clinical Guidelines present statements of 'Best Practice' based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women's this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it.
Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women's Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated
In view of the possibility of human error and / or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site.
You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner. NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines.
Additional Clinical Information: Fetal Scalp Lactate Sampling
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Continuous EFM during labour is associated with a reduction in neonatal seizures but no significant differences in rates of cerebral palsy, perinatal mortality, low Apgar scores, and admission to neonatal intensive care or hypoxic ischaemic encephalopathy 3 . This may be because the incidence of these conditions is too low or conditions such as cerebral palsy occur antenatally rather than intrapartum so that EFM would be unlikely to have an effect. Continuous EFM is associated with an increase in caesarean section and instrumental vaginal births. FBS, based on pH analysis during the first stage of labour was introduced by Saling in 1962 5 . 30 to 50 microlitres of blood are required for pH analysis and it has been reported to fail in 20% of cases 6 . Owing to the practical limitations associated with blood sampling for pH measurement, work commenced on developing a simpler method. The measurement of intrapartum fetal scalp lactate has been studied since the 1970s but previous methods for lactate measurement required large amounts of blood and laboratory resources and were therefore not clinically useful.
Lactate in first stage of labour:
The relationship between maternal and fetal lactate concentrations in labour has been studied. No significant correlation was demonstrated between the duration of the first stage of labour and fetal lactate concentration at the beginning of the second stage of labour 7, 9 . This confirms previous findings suggesting that in the absence of hypoxia, fetal lactate concentrations are constant during the first stage of labour 8 .
Lactate in the second stage of labour:
Maternal lactate concentrations increase significantly during the active phase of the second stage of labour. The source of this lactate is thought to be maternal skeletal muscles. It is estimated that the maternal lactate increases by 2mmol/L for every 30 minutes of active pushing
10
. The fetal lactate also rises during active pushing when it is estimated to increase by 1mmol/L for every 30 minutes of active pushing. The question of whether this lactate rise is driven by fetal hypoxia or derived from the mother has been investigated by studying the arterio-venous lactate difference at delivery. The results suggest that the main contributor to the fetal lactate increase is the fetus itself, especially with a prolonged second stage
. Animal studies support these results
11
. These findings suggest that a fetal scalp lactate is an appropriate indicator of fetal hypoxia in the passive second stage, for example whilst awaiting further descent of the presenting part. After the commencement of active pushing however, lactate will rise as suggested above.
Normal (aerobic) metabolism: when the fetus is well oxygenated, the fetus generates energy in the form of adenosine triphosphate (ATP), from glucose, forming pyruvate. This pyruvate is further metabolised in the presence of oxygen to form carbon dioxide and water with the release of ATP for cellular metabolism. The carbon dioxide and water are easily eliminated from the fetus across the placenta. Abnormal (anaerobic) metabolism: when the fetus is short of oxygen (hypoxic) there is insufficient oxygen for the aerobic metabolism of pyruvate. Instead pyruvate is converted into a small amount of ATP as well as lactic acid and hydrogen ions which accumulate resulting in increased lactate levels (metabolic acidosis) 12 . Nonreassuring CTG patterns may reflect the ability of the individual fetus to adapt to decreases in oxygen supply. Inadequate oxygen supply results in anaerobic metabolism of glucose, which leads to metabolic acidosis 12 . Lactate sampling gives an assessment of metabolic acidosis. Full analysis of acid-base balance including base deficit is required to discriminate between respiratory and metabolic acidosis.
Umbilical cord blood lactate concentrations in newborns:
Umbilical cord blood lactate concentrations in newborns were studies in order to establish reference ranges 13 . 10,169 "vigorous" newborns, presumably healthy, delivered vaginally either spontaneously or by instrumental delivery were included. Babies with complicated pregnancies and those delivered by CS were excluded. The variation in lactate values at term ranged from a mean of 3.5mmol/L at 37 weeks' gestation to a mean of 4.3mmol/L at 42 weeks' gestation. Based on these data, the use of the accepted cut-off value for fetal scalp lactate of 4.8mmol/L would not result in any unnecessary interventions even in babies at 42 weeks' gestation.
CTG abnormalities during the ACTIVE second stage of labour require consideration of expedited delivery NOT further assessment by FBS.
